ARHGAP8: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Target Name: ARHGAP8

NCBI ID: G23779

ARHGAP8

ARHGAP8: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Guanosine triphosphate (GTP) is a key regulatory molecule in various cellular processes, including vesicle traffic, intracellular signaling, and DNA replication. GTPase-activating proteins (GAPs) are a family of proteins that play a crucial role in regulating GTPase activity by activating or inhibiting GTP binding. Rho-type GAPs are a subfamily of GAPs that are characterized by the presence of a regulatory protein called RhoA. RhoA functions as a scaffold protein to recruit other GAPs and to regulate their activity.

ARHGAP8 is a Rho-type GAP that is expressed in various tissues and cells. It is a 21-kDa protein that contains a N-terminal catalytic domain, a central 尾-sheet, and a C-terminal T-loop. The ARHGAP8 protein is highly conserved and has a similar structure to other Rho-type GAPs, such as ARHGAP1 and ARHGAP2.

ARHGAP8 functions as a GAP by activating GTPases in various cellular processes. It can activate the GTPase activity of several target proteins, including the protein kinase IP3-GAP (IP3-GTPase-activating protein), which is involved in intracellular signaling, and the protein SMIP (Sar-regulated intracellular signaling protein), which is involved in vesicle traffic.

In addition to its function as a GAP, ARHGAP8 may also be a potential drug target. Several studies have suggested that ARHGAP8 may be involved in various cellular processes, including intracellular signaling, cell survival, and cell migration. Therefore, targeting ARHGAP8 may be a promising strategy for the development of new therapeutic approaches for various diseases.

ARHGAP8 has also been identified as a potential biomarker for several diseases, including cancer. Several studies have shown that ARHGAP8 is expressed in various cancer tissues and that it is involved in various cellular processes that are associated with cancer progression. Therefore, targeting ARHGAP8 may be a promising strategy for the development of new diagnostic tools and therapeutic approaches for cancer.

In conclusion, ARHGAP8 is a Rho-type GAP that is involved in various cellular processes and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of ARHGAP8 in cellular processes and to develop new therapeutic approaches based on this protein.

Protein Name: Rho GTPase Activating Protein 8

Functions: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state

The "ARHGAP8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets